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Supplementary Methods
The CHAPAS-3 (Children with HIV in Africa -Pharmacokinetics and Adherence of Simple antiretroviral regimens) trial recruited children from Zambia (University Teaching Hospital, Lusaka) and Uganda (BaylorUganda Centre of Excellence, Kampala; Joint Clinical Research Centre, Kampala and Gulu (satellite site)).
(a) Eligibility criteria
Confirmed HIV-infected children aged 1 month to 13 years weighing 3-30kg were enrolled if they were: (1) previously untreated and met WHO 2010 criteria for ART (ART-naïve), or (2) on stavudine-containing ART for ≥2 years with screening viral load (VL) <50 copies/ml and stable CD4/CD4% (ART-experienced). ARTexperienced children had to have no signs of lipodystrophy, and in Uganda ART-naïve children had to be <5 years old (following national guidelines for receiving stavudine). Children with acute infections, on medications contraindicated with ART (including tuberculosis treatment in those <3 years who would need to receive triple NRTI rather than nevirapine), unlikely to adhere or attend, with laboratory abnormalities contraindicating ART or perinatally exposed to ART (including single-dose nevirapine) and aged <1 year were ineligible.
(b) Sample size calculation from the trial protocol
Assuming that children were enrolled over 18 months and followed for a minimum of 2 years, cumulative lost-to-followup/ death was 20% at the end of the 3.5 year period, and incidence of the primary toxicity endpoint on d4T containing regimens was 20% per year (approximately twice the rate of adverse events leading directly to ART substitutions in adults 1 ), then 470 children would provide at least 85% power to detect reductions in toxicity incidence to 10% per year (HR=0.50) across the three arms, and 80% power to detect reductions to 10.5% per year (HR=0.525). If the toxicity rates were in fact half this, ie only 10% per year, 470 children would provide at least 85% power to detect larger reductions in toxicity incidence to 3.7% per year (HR=0.37) across the three arms. We consider that if the true rate of the primary toxicity endpoint is only 10% per year in children, then such larger improvement would be needed to justify changing policy to recommending different first-line drugs.
Randomising a total of 470 children would provide at least 80% power to detect differences of 0.55 units between randomised arms within each strata in the change in age-adjusted skinfold thicknesses (assuming standard deviation for the change in z-score from baseline is 1.6, 2 and 25% missing measurements at 96
weeks from death/lost to follow-up or missing value). The entire group of 470 patients would provide 85%
power to detect smaller differences of 0.4 units. Of note, the normal range (5th to 95th percentile) corresponds to a z-score of -2 to +2: so, for example a difference of 0.55 units is the difference between the 10th and 23rd percentile, or between the 25th and 40th percentile, differences which we consider to be clinically relevant.
(c) Statistical methods
Time-to-event analyses measured time from randomization, censored at the last clinical follow-up if the outcome had not occurred.
Weight, height, BMI, skinfold thicknesses, body circumferences and CD4 were compared between randomized groups over time using generalized estimating equations (GEE) (independent correlation structure) with randomized group, stratification factors and scheduled visit week as categorical independent variables, adjusting for baseline value. An interaction term was included between ART-naïve vs experienced and randomized group as this was the primary exposure over which effects of randomised group were considered might differ. The closest measurement to each scheduled visit date within equally spaced windows was used as the measurement at each scheduled visit. Continuous measurements were modeled using change from baseline as the outcome in a normal GEE model. Adherence measures were modeled as dichotomous outcomes in a binomial GEE model. Baseline values were those nearest to but before and within 42 days of randomization.
For all analyses global significance tests pool comparisons between randomised groups across strata, and heterogeneity tests assess whether differences between NRTIs vary between strata.
Weight/height-for-age Z-scores were calculated using UK 1990 reference data 3 which covers the full age range of CHAPAS-3 children. Body circumference and skinfold measurement Z-scores were calculated using Dutch reference data 4, 5 as there are no African reference data; raw measurements were used in secondary analyses. Four composite measures were also considered, namely waist:hip, waist:MUAC, torso:arm ratios and the sum of subscapular, suprailiac, biceps and triceps skinfold thicknesses. 6 Drug susceptibility was estimated from genotype according to the Stanford algorithm v7.0.
Supplementary Results
For the primary endpoint (figure 2a) there were 835 events in 269(74%) ART-naïve children versus 82 events in 43(38%) ART-experienced children. For serious adverse events, most events (163/199, 82%) caused or prolonged hospitalisation, and the most common diagnoses were pneumonia (67), malaria (34) and septicaemia/bacteraemia (24).
The Endpoint Review Committee (ERC) adjudicated the relationship of each primary endpoint to each of stavudine, zidovudine and abacavir blind to the NRTI actually received, so toxicity from any of the three NRTIs could be attributed to each event. Of note, whilst this objectively assigned specific toxicities to events (eg anaemia of a similar severity would be classified as possibly zidovudine-related regardless of NRTI received), it also meant that the child might not be receiving the drug adjudicated as possibly related by the ERC. The three children who stopped nevirapine following hypersensitivity reactions were all ART naïve at randomisation and aged between 18 months and 3 years. The reactions occurred between two and four weeks after ART initiation; in each case nevirapine was substituted with lopinavir/ritonavir and the child then continued in the trial until study closure.
There were few differences between randomised groups in changes in body circumferences and skinfold thicknesses, and those that occurred were not consistent in their direction between randomised groups (supplementary tables 2 and 3, supplementary figure 1). Increases in calf circumference were smaller in children on abacavir (p=0.01); reduction in supra-iliac skinfold was greater in naïve children on zidovudine and in experienced children on abacavir (p=0.01).
Weight gain was rapid among ART-naïve children (mean weight-for-age Z-score greater than -1 in all randomised groups at 48 weeks), as was CD4% recovery, with mean CD4% above 30% in all groups at 48 weeks (supplementary 
